Gr. Sarantis S.A., together with its subsidiaries, produces and trades in cosmetics, household products, and pharmaceutical items in Greece, Portugal, Poland, Romania, Bulgaria, Serbia, Bosnia and Herzegovina, North Macedonia, Slovenia, Croatia, Czech-Slovakia, Hungary, and Ukraine. It operates through Beauty/Skin/Sun Care, Personal Care, Home Care Solutions, Private Label, and Strategic Partnerships segments. The company offers personal and health care products, including food supplements, health and self-care, baby care, body wash, deodorants, fragrances, grooming, hair care and styling, hand wash, oral care, personal hygiene, and skin and sun care. It also provides home care and professional products, such as cleaning tools, detergents, packaging, bathroom cleaners, concentrated fabric softeners, dishwashing, drainer care, food packaging, garbage bags, insect control, septic tank activator, and shoe care; and luxury cosmetics comprising candles, home fragrances, and makeup and treatment products. The company also exports its products to rest of Europe, Asia, the Middle East, Oceania, and the United States. Gr. Sarantis S.A. was founded in 1930 and is based in Athens, Greece.…
What Is Novartis (SWX:NOVN) Gaining From Its PMR Approval And ADC Deal?
Gr. Sarantis (ATH: SAR) is listed on Athens Exchange, where its shares trade in EUR. It belongs to the Household & Personal Products industry, part of the Consumer Defensive sector, and reports about 2,619 employees.
The shares were at 12.04 EUR on 20 November 2026, down 0.8% over 52 weeks. Its 52-week range is 10.78 EUR to 15.82 EUR: the price is 23.9% below the high and 11.7% above the low.
At a market capitalisation of 759.03M EUR, it trades at 15.1 times trailing earnings and 12.5 times forward earnings. The median trailing P/E of its 20 largest Household & Personal Products peers is 18.8, a discount of 20% for SAR. It pays a dividend yielding 3.20% (it pays out 49% of its earnings), against a median of 2.59% among the dividend payers in that peer group.
Gr. Sarantis reports return on equity of 13.2%, an operating margin of 10.8% and revenue up 1.3% year over year.
Its debt exceeds its cash by 68.00M EUR, a debt-to-equity ratio of 0.15. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 15.00 EUR is 24.6% above the current price. The next earnings report is expected on 11 March 2027.